TesaBio.ai Raises Pre-Seed Round from GRIDX

Tesabio.ai, an AI-first therapeutics company pioneering the discovery of small molecules that restore microRNA network balance in complex diseases, has officially emerged from stealth. The company announced the closing of its pre-seed funding round led by GRIDX, marking GRIDX’s first investment in a biotech startup co-founded by Paraguayan and American entrepreneurs.

Tesabio.ai was founded by Sebastián Ortiz Chamorro (CEO), Diego Galeano (CTO), and Afshin Beheshti (CSO), and is supported by a world-class Scientific Advisory Board that includes Prof. Frank Slack (Harvard Medical School), Dr. Charles Vanderburg (Broad Institute), and Prof. Christopher Mason (Cornell University).

The company’s proprietary AI platform identifies small molecules capable of modulating disease-related microRNA networks, offering a new therapeutic paradigm beyond single-microRNA targeting. Tesabio’s technology has already demonstrated promising early validation in models of metastatic breast cancer and anemia.

“We’re building the next generation of therapeutics by teaching AI to restore the biological balance that diseases disrupt,” said Sebastian Ortiz, co-founder and CEO. “This partnership with GRIDX is a major milestone for biotech innovation in Latin America.”

Read the announcement from GRIDX here.